Abstract

COVID-19 causes immune perturbations which may persist long-term, and patients frequently report ongoing symptoms for months after recovery. We assessed immune activation at 3-12 months post hospital admission in 187 samples from 63 patients with mild, moderate or severe disease and investigated whether it associates with long COVID. At 3 months, patients with severe disease displayed persistent activation of CD4+ and CD8+ T-cells, based on expression of HLA-DR, CD38, Ki67 and granzyme B, and elevated plasma levels of IL-4, IL-7, IL-17 and TNF-α compared to mild and/or moderate patients. Plasma from severe patients at 3 months caused T-cells from healthy donors to upregulate IL-15Rα, suggesting that plasma factors in severe patients may increase T-cell responsiveness to IL-15-driven bystander activation. Patients with severe disease reported a higher number of long COVID symptoms which did not however, correlate with cellular immune activation/pro-inflammatory cytokines after adjusting for age, sex and disease severity. Our data suggests that long COVID and persistent immune activation may correlate independently with severe disease.

Data availability

All data generated or analysed during this study are included in the manuscript files or supplementary files. Raw file (FCS files) for all flow cytometry data have been deposited in the FlowRepository, the link for access to the data is provided in the Material and Methods, Flow cytometry data analysis section.The code script and data for the analysis in Figure 6 are publicly available here: https://github.com/gushamilton/discover_long_covid. The link is provided in the Material and Methods, statistical analysis section.

The following data sets were generated

Article and author information

Author details

  1. Marianna Santopaolo

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Michaela Gregorova

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1605-0558
  3. Fergus Hamilton

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. David Arnold

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Anna Long

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Aurora Lacey

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Alice Halliday

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Holly Baum

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1311-6446
  9. Kristy Hamilton

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Rachel Milligan

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Elizabeth Oliver

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1211-1942
  12. Olivia Pearce

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Lea Knezevic

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Begonia Morales Aza

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Alice Milne

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Emily Milodowski

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Eben Jones

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Rajeka Lazarus

    University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Anu Goenka

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Adam Finn

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Nicholas Maskell

    Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  22. Andrew D Davidson

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1136-4008
  23. Kathleen Gillespie

    Diabetes and Metabolism, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  24. Linda Wooldridge

    Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6213-347X
  25. Laura Rivino

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    For correspondence
    laura.rivino@bristol.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6213-9794

Funding

Wellcome Trust (Elizabeth Blackwell Institute (EBI) with funding from the University's alumni and friends)

  • Anu Goenka
  • Linda Wooldridge
  • Laura Rivino

Southmead Hospital Charity (DISCOVER)

  • Fergus Hamilton
  • David Arnold
  • Laura Rivino

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Information regarding our ethics approval and consent process is provided in the Materials and Methods section and copied below.Patients hospitalized with COVID-19 ({greater than or equal to}18 years of age) were recruited between 30th March and 3rd June 2020 into the observational study DIagnostic and Severity markers of COVID-19 to Enable Rapid triage (DISCOVER), a single-centre prospective study based in Bristol (UK). Research Ethics Committee (REC) approval: REC:20/YH/1021. Survivors were invited at 3, 8 and 12 months post admission to attend outpatient follow up clinics for a systematic clinical assessment (Arnold et al 2020). For those patients attending a face-to-face follow-up, consent was taken to collect samples for research purposes (blood for PBMC isolation, plasma and serum). When available serum collected from patients at admission was made available to the research team.

Copyright

© 2023, Santopaolo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,758
    views
  • 427
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marianna Santopaolo
  2. Michaela Gregorova
  3. Fergus Hamilton
  4. David Arnold
  5. Anna Long
  6. Aurora Lacey
  7. Alice Halliday
  8. Holly Baum
  9. Kristy Hamilton
  10. Rachel Milligan
  11. Elizabeth Oliver
  12. Olivia Pearce
  13. Lea Knezevic
  14. Begonia Morales Aza
  15. Alice Milne
  16. Emily Milodowski
  17. Eben Jones
  18. Rajeka Lazarus
  19. Anu Goenka
  20. Adam Finn
  21. Nicholas Maskell
  22. Andrew D Davidson
  23. Kathleen Gillespie
  24. Linda Wooldridge
  25. Laura Rivino
(2023)
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months
eLife 12:e85009.
https://doi.org/10.7554/eLife.85009

Share this article

https://doi.org/10.7554/eLife.85009

Further reading

    1. Evolutionary Biology
    2. Immunology and Inflammation
    Shang Geng, Xing Lv ... Tianjun Xu
    Research Article

    The incessant arms race between viruses and hosts has led to numerous evolutionary innovations that shape life’s evolution. During this process, the interactions between viral receptors and viruses have garnered significant interest since viral receptors are cell surface proteins exploited by viruses to initiate infection. Our study sheds light on the arms race between the MDA5 receptor and 5’ppp-RNA virus in a lower vertebrate fish, Miichthys miiuy. Firstly, the frequent and independent loss events of RIG-I in vertebrates prompted us to search for alternative immune substitutes, with homology-dependent genetic compensation response (HDGCR) being the main pathway. Our further analysis suggested that MDA5 of M. miiuy and Gallus gallus, the homolog of RIG-I, can replace RIG-I in recognizing 5’ppp-RNA virus, which may lead to redundancy of RIG-I and loss from the species genome during evolution. Secondly, as an adversarial strategy, 5’ppp-RNA SCRV can utilize the m6A methylation mechanism to degrade MDA5 and weaken its antiviral immune ability, thus promoting its own replication and immune evasion. In summary, our study provides a snapshot into the interaction and coevolution between vertebrate and virus, offering valuable perspectives on the ecological and evolutionary factors that contribute to the diversity of the immune system.

    1. Chromosomes and Gene Expression
    2. Immunology and Inflammation
    Matthew C Pahl, Prabhat Sharma ... Andrew D Wells
    Research Article

    Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis-regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.